NextFin News - Researchers at the Icahn School of Medicine at Mount Sinai have successfully mapped a coordinated gene expression program that tracks directly with neurotransmission in the living human brain, a breakthrough that effectively bridges the gap between molecular biology and real-time neural signaling. The study, published in Molecular Psychiatry, utilized intracranial recordings from more than 100 neurosurgery patients to identify a reproducible set of genes that activate in sync with the brain’s electrical and chemical communication. By moving beyond the static "snapshots" provided by postmortem tissue, the team has established a dynamic molecular framework for understanding how the human brain processes thought, emotion, and behavior in real time.
For decades, the gold standard for studying the human brain’s genetic architecture was the analysis of deceased tissue. While these studies provided a foundational map of where genes are located, they were fundamentally incapable of showing which genes are "turned on" during active cognition. Neurotransmission is a high-speed, energy-intensive process; studying it in a postmortem state is akin to examining a parked car to understand the mechanics of a high-speed chase. The Mount Sinai team bypassed this limitation by integrating electrophysiological data—direct measures of brain waves—with transcriptomic profiling of the prefrontal cortex while patients were undergoing surgery. This approach allowed them to see the molecular "software" running as the electrical "hardware" fired.
The identified transcriptional program is not a random collection of active genes but a highly coordinated system aligned with excitatory neuronal signaling and synaptic function. This discovery suggests that the brain maintains a specific genetic standby mode, ready to facilitate the split-second signals required for human consciousness. Alexander Charney, a lead investigator on the study, noted that the findings represent a major shift toward "living biology," allowing scientists to examine the molecular architecture of neurotransmission as it happens. The reproducibility of this program across independent patient cohorts confirms that these genetic patterns are a fundamental, rather than incidental, feature of human brain biology.
The implications for the pharmaceutical and biotech sectors are substantial. Current treatments for psychiatric disorders like depression and schizophrenia largely target neurotransmitters themselves—such as serotonin or dopamine—often with a "one-size-fits-all" approach that fails a significant percentage of patients. By identifying the specific genes that control the machinery of these signals, the industry can pivot toward precision medicine. This could involve developing small-molecule drugs that target the gene expression program itself or refining neuromodulation techniques, such as deep brain stimulation, to better align with a patient’s unique molecular profile.
Beyond psychiatric applications, the study offers a roadmap for addressing epilepsy and neurodegenerative diseases where signaling pathways are known to be compromised. Brian Kopell, Director of the Center for Neuromodulation at Mount Sinai, emphasized that pairing intracranial recordings with molecular profiling bridges two worlds that have traditionally operated in silos. This integration provides a clearer picture of how neural circuits operate at both the electrical and genetic levels, potentially leading to diagnostic tools that can detect molecular signaling failures long before physical symptoms of cognitive decline appear.
The research also highlights a broader trend in neuroscience: the move toward multi-omic integration. By combining large-scale transcriptomic data with direct physiological measures, researchers are beginning to decode the "functional genome." This shift is likely to accelerate as surgical technologies and genomic sequencing become more sophisticated and less invasive. The ability to map the living brain’s genetic activity provides a new lens through which to view human vulnerability to disease, suggesting that many disorders may stem not from a lack of neurotransmitters, but from a failure of the underlying genetic program to coordinate their release and reception.
Explore more exclusive insights at nextfin.ai.
